Heterogeneous Nuclear Ribonucleoprotein A2 B1 (Hnrnpa2B1) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
.infobox.infobox-gene
!! HNRNPA2B1 - Heterogeneous Nuclear Ribonucleoprotein A2/B1
| Gene Symbol | HNRNPA2B1 |
| Full Name | Heterogeneous Nuclear Ribonucleoprotein A2/B1 |
| Chromosome | 7 |
| Location | 7p15.2 |
| NCBI Gene ID | 3181 |
| OMIM | 600124 |
| UniProt | P22626 |
| Associated Diseases | Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Multisystem Proteinopathy |
Gene Symbol: HNRNPA2B1
Full Name: Heterogeneous Nuclear Ribonucleoprotein A2/B1
Chromosomal Location: 7 7p15.2
HNRNPA2B1 is a member of the hnRNP A2/B1 family of RNA-binding proteins. It participates in pre-mRNA processing, mRNA stability, and RNA transport. The protein is alternatively spliced to generate multiple isoforms with distinct functions.
The P195L and D262V mutations in HNRNPA2B1 are associated with familial ALS and MSP. These mutations promote the formation of cytoplasmic inclusions containing HNRNPA2B1 and other RNA-binding proteins. The aggregates disrupt normal RNA granule dynamics.
Research into HNRNPA2B1 mutations provides insights into neurodegenerative disease mechanisms and potential therapeutic targets. Gene therapy approaches targeting RNA metabolism and protein aggregation are being explored.
The study of Heterogeneous Nuclear Ribonucleoprotein A2 B1 (Hnrnpa2B1) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
HNRNPA2B1 (Heterogeneous Nuclear Ribonucleoprotein A2/B1) is a member of the hnRNP A/B family of RNA-binding proteins. These proteins are involved in various aspects of RNA metabolism including pre-mRNA processing, mRNA splicing, stability, localization, and transport. HNRNPA2B1 is particularly important in neuronal RNA processing and has been strongly implicated in neurodegenerative diseases.
Key molecular functions include:
Alternative Splicing: HNRNPA2B1 regulates alternative splicing of pre-mRNAs by binding to intronic splicing regulatory elements. It can promote inclusion or exclusion of specific exons in target transcripts.
mRNA Stability and Transport: The protein binds to AU-rich elements and other regulatory sequences to stabilize mRNAs and facilitate their transport from the nucleus to the cytoplasm and within neuronal processes.
RNA Granule Formation: HNRNPA2B1 is a component of stress granules, processing bodies (P-bodies), and neuronal RNA granules that regulate mRNA translation and degradation.
Telomere Maintenance: HNRNPA2B1 associates with telomeres and regulates telomere length and function through interaction with telomerase.
HNRNPA2B1 is ubiquitously expressed with highest levels in:
In the nervous system, HNRNPA2B1 is expressed in:
The protein localizes to both nuclear and cytoplasmic compartments, with dynamic shuttling between these compartments depending on cellular conditions.
HNRNPA2B1 is one of the most frequently mutated RNA-binding proteins in ALS and frontotemporal dementia (FTD):
Targeting HNRNPA2B1 for therapeutic benefit:
Antisense Oligonucleotides: ASOs can be designed to:
Small Molecule Modulators: Compounds that:
Gene Therapy: Viral delivery of wild-type HNRNPA2B1 to compensate for loss-of-function mutations
HNRNPA2B1 participates in multiple cellular pathways:
Key protein interactions:
Kim HJ, Kim NC, Wang YD, et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature. 2013;495(7442):467-473. PMID:23455423
Martinez FJ, Pratt GA, Van Nostrand EL, et al. Regulation of neuronal development and function by RNA-binding proteins in the CNS. Nat Rev Neurosci. 2016;17(5):301-315. PMID:27053247
Liu EY, Cali CP, Lee EB. RNA metabolism in neurodegenerative disease. Brain Res. 2019;1727:146555. PMID:30471281
Oberstadt M, Claussen N, Stieler J, et al. TDP-43 and its contribution to neurodegeneration. Neurochem Int. 2018;130:104318.
Ling JP, Pletnikova O, Troncoso JC, Wong PC. TDP-43 deposition in prospectively studied, cryopreserved brains. Acta Neuropathol. 2015;130(1):63-72.
Baralle M, Buratti E, Baralle FE. The role of TDP-43 in ALS and FTD. J Neurol Sci. 2013;333(1-2):11-15.
Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130-133.
Guo L, Shorter J. Biology and pathobiology of prion-like domain proteins in neurodegeneration. Nat Med. 2015;21(11):1158-1167.